Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...
The GLP-1 phenomenon is making the fragmentation and dysfunction of the U.S. health care system even more apparent.
Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do ...